Through TrialHub's data intelligence gathering platform, EmVenio can easily identify optimal markets to attract clinical trial participants who are needed ...
The study, consisting of single ascending-dose cohort and multiple ascending-dose cohort, has dosed the first of 36 planned study subjects. The Phase I cli...
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization ...
IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") announced the execution of a Research Grant Agreement with Karolinska Unive...
The partners continue working closely on matters concerning pending approval in the U.S. for AVT02, an interchangeable high-concentration biosimilar candid...
PromoExQ MSC Growth Medium XF enables the long-term expansion of a variety of MSC types, including MSCs from the bone marrow, umbilical cord matrix, and ad...
According to data released by GLOBOCAN 2020, lung cancer is currently the most prevalent malignant tumor with the highest mortality rate in China. Small ce...
Massive Bio, an AI-powered platform connecting patients with clinical trials and CureMatch, a healthcare technology company leveraging Knowledge Representa...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon p...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the expansion of its digital PCR (dPCR) offering for the development of cell and gene th...
Through this collaboration, the companies aim to identify novel molecules that promote precise delivery of nucleic acid by leveraging Eleven's innova...
"Blood cancers are a complex, heterogeneous set of diseases and while the treatment landscape has advanced in recent years, there is still a lot we don't k...
Join us for an in-depth conversation with Chua Keng Hock as we explore the challenges, strategies, and future prospects of the biopharma industry in today'...
Phase III OCARINA II trial met primary and secondary endpoints OCREVUS twice a year, 10-minute injection has the potential to further improve the treatm...
© 2025 Biopharma Boardroom. All Rights Reserved.
